Competitive inhibitor of protein kinase G type I alpha and I beta and of cGMP-gated retinal type ion channels (cyclic GMP antagonist). Resistant against mammalian cyclic nucleotide- dependent phosphodiesterases, no metabolic side effects. More lipophilic and membrane permeant compared to Rp-8-pCPT-cGMPS (Prod. No.
BLG-C013).
PRODUCT PROPERTIES |
Alternative Name: | | β-Phenyl-1,N2-etheno-8-bromoguanosine-3',5'-cyclic monophosphorothioate . sodium salt, Rp-isomer |
Formula: | | C18H14BrN5O6PS . Na |
MW: | | 562.3 |
CAS: | | 172806-20-1 |
Quantity: | | 1µmol=~0.6mg |
Purity: | | > 99% HPLC |
Appearance: | | Lyophilized or crystallized sodium salt. |
Solubility: | | Limited solubility in water or buffer. |
Reconstitution: | | Rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing. |
Long Term Storage: | | -20°C |
Background / Technical Information: | | For the Original Manufacturer's data sheet please click here. |
|
|
|
Product Literature References
Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP-dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial: C. Zaragoza, et al.; Mol. Pharmacol.
62, 927 (2002),
Abstract;
Effects of SQ 22536, an adenylyl cyclase inhibitor, on isoproterenol-induced cyclic AMP elevation and relaxation in newborn ovine pulmonary veins: Y. Gao & J. Usha Raj; Eur. J. Pharmacol.
436, 227 (2002),
Abstract;
Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling: C. Ibarra-Alvarado, et al.; Mol. Pharmacol.
61, 312 (2002),
Abstract;
Full Text